Identification of oncogenic driver mutations by genome-wide CRISPR-Cas9 dropout screening.
Genome-wide CRISPR-Cas9 dropout screens can identify genes whose knockout affects cell viability. Recent CRISPR screens detected thousands of essential genes required for cellular survival and key cellular processes; however discovering novel lineage-specific genetic dependencies from the many hits still remains a challenge.



To assess whether CRISPR-Cas9 dropout screens can help identify cancer dependencies, we screened two human cancer cell lines carrying known and distinct oncogenic mutations using a genome-wide sgRNA library. We found that the gRNA targeting the driver mutation EGFR was one of the highest-ranking candidates in the EGFR-mutant HCC-827 lung adenocarcinoma cell line. Likewise, sgRNAs for NRAS and MAP2K1 (MEK1), a downstream kinase of mutant NRAS, were identified among the top hits in the NRAS-mutant neuroblastoma cell line CHP-212. Depletion of these genes targeted by the sgRNAs strongly correlated with the sensitivity to specific kinase inhibitors of the EGFR or RAS pathway in cell viability assays. In addition, we describe other dependencies such as TBK1 in HCC-827 cells and TRIB2 in CHP-212 cells which merit further investigation.



We show that genome-wide CRISPR dropout screens are suitable for the identification of oncogenic drivers and other essential genes.
Department of Gastroenterology and Hepatology, University Hospital Zürich, Zürich, Switzerland.
Michael K
MK
Kiessling
Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel, Switzerland.
Sven
S
Schuierer
Institute of Medical Virology, University of Zürich, Zürich, Switzerland.
Silke
S
Stertz
Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel, Switzerland.
Martin
M
Beibel
Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel, Switzerland.
Sebastian
S
Bergling
Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel, Switzerland.
Judith
J
Knehr
Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel, Switzerland.
Walter
W
Carbone
Department of Gastroenterology and Hepatology, University Hospital Zürich, Zürich, Switzerland.
Cheryl
C
de Vallière
Department of Oncology, Children University Hospital Zürich, Zürich, Switzerland.
Joelle
J
Tchinda
Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel, Switzerland.
Tewis
T
Bouwmeester
Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel, Switzerland.
Klaus
K
Seuwen
Department of Gastroenterology and Hepatology, University Hospital Zürich, Zürich, Switzerland. Gerhard.rogler@usz.ch.
Gerhard
G
Rogler
Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel, Switzerland. Guglielmo.roma@novartis.com.
Guglielmo
G
Roma
D064113:CRISPR-Cas Systems; D017871:Calcium-Calmodulin-Dependent Protein Kinases / Q000378:metabolism; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects / Q000235:genetics; D002471:Cell Transformation, Neoplastic / Q000235:genetics*; D004354:Drug Screening Assays, Antitumor; D055786:Gene Knockout Techniques; D055106:Genome-Wide Association Study; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000378:metabolism; D009154:Mutation; D009857:Oncogenes; D010641:Phenotype; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism; D000094704:RNA, Guide, CRISPR-Cas Systems / Q000235:genetics
D047908:Intracellular Signaling Peptides and Proteins; D047428:Protein Kinase Inhibitors; D000094704:RNA, Guide, CRISPR-Cas Systems; D017346:Protein Serine-Threonine Kinases; C403191:TBK1 protein, human; D017871:Calcium-Calmodulin-Dependent Protein Kinases; C489044:TRIB2 protein, human
Driver mutations; Dropout; EGFR; Kinase; NRAS; Negative selection; Whole genome CRISPR screen